Reach & Teach Physicians with Virtual Reality: Viscira’s “EyeMAC” Wet AMD Simulation Exhibit
A conversation with Dave Gulezian, President and CEO of Viscira, about the use of virtual reality simulation to reach and teach physicians at medical conventions. Featured is his company's
Pharma’s Social Media Working Group: Who It Consists of, How It Formed, and What...
A conversation with Craig M. Audet, Vice-President and Head of the US Regulatory Affairs Marketed Products Group at sanofi-aventis, Mark Gaydos, Senior Director, U.S. Regulatory Affairs Marketed Products at sanofi-aventis, and Cynthia Phillips, Sr Dir Labeling and Promotional Compliance at Millennium Pharmaceuticals, about their views on how pharmaceutical companies should handle posts made on social media sites owned or sponsored by them. Of particular interest are posts that mention off-label indications or adverse events.
Is the M&A Frenzy Short-Circuiting Pharma R&D? A Former Researcher Speaks Out
A conversation with Kenneth 'Eric' Milgram, Ph.D., Principal, Applied Scientific Consulting, former Director, Systems Biology Technologies at Wyeth Pharmaceuticals/Pfizer, about what happens to pharmaceutical companies when they put Wall Street expectations ahead of science-driven innovation.
ACOR: An Online Social Networking Community of Cancer Patients & Caregivers Pharma Can’t Join...
A conversation with Gilles Frydman, founder of the Association of Online Cancer Resources, about how this venerable and vibrant online community has helped more than 600,000 cancer sufferers and caregivers for over 13 years!
Fear & Loathing in Washington, DC: Takeaways from the FDA Public Hearing
Speakers, attendees and ePharma Pioneer Club members discuss the key takeaways of FDA's November 12-13 public hearing on the use of social media by the pharmaceutical industry. What key points were made? What questions were asked by FDA? What are the next steps?
Novo Nordisk’s Race With Insulin Campaign: It’s Not Just About Twitter
A conversation with Ambre Morley, Associate Director, Product Communications, Novo Nordisk Inc., about Novo Nordisk's Race With Insulin Campaign, which includes a branded Twitter account (@racewithinsulin). Ambre will talk about Novo Nordisk's social media goals, but also include other integrated aspects of the campaign.
Risk Mitigation and Its Impact on Pharma Marketing
A conversation with Jeff Fetterman, President and CEO of ParagonRx, about developing a Risk Evaluation and Mitigation Strategy (REMS) that clinicians will consider useful and that would raise their intent to prescribe.
A Solution to the Problem of Inaccurate Dosing of OTC Pediatric Medicines
A conversation with Brian Kaplan M.D., founder, and Bob Terwilliger, CEO & President, of AccuDial Pharmaceutical about the safety and efficacy of over-the-counter (OTC) medications for children and their company's patented weight-based dosing labeling product.
Avoid the Pitfalls and Pratfalls of Social Media: Ask the Gang of Four Pharma...
Jonathan Richman, Wendy Blackburn, Silja Chouquet, Steve Woodruff and other speakers from eyeforpharma's 4th Annual eCommunications & Online Marketing Summit (plus invited ePharma Pioneer Club members) will discuss how pharmaceutical marketers and communications professionals can avoid typical social media pitfalls (eg, FDA warning letters) and pratfalls (eg, using the wrong Twitter hashtag). It's really a free-for-all roundtable discussion among Twitterati and eCommunication industry experts who will be attending and/or speaking at this important conference.
Meet Digital Pharma’s Faculty: What’s Hot and What’s Not?
Shwen Gwee and other Digital Pharma 'unconference' faculty members will discuss what's hot and what's not in digital pharma marketing. It's also your opportunity to vent your favorite digital pharma rant! Or just quietly suggest additional topics to be covered at the conference.
